Ignyta enters exclusive worldwide license with Nerviano

In October 2013 Ignyta entered into an exclusive worldwide license with Nerviano for an ALK inhibitor drug candidate RXDX-101 (not clear if RXDX-101 is the same as NMS-E628 or different).

Ignyta is a biotech startup in San Diego. Ignyta plans to continue/accelerate Nerviano’s Phase 1 trial and expand it into Phase 2. Nerviano’s drug was designed to get across the blood brain barrier and is a TRK and ROS inhibitor.

Here is a link with more details: http://www.ignyta.com/PDF/Ignyta%20Presentation_Jan%202014_20140110%20Final.pdf

This entry was posted in Brain metastases, Lung cancer, NMS-E628, Research. Bookmark the permalink.

Leave a Reply